Effect of aldosterone receptor antagonist on obesity-related glomerulonephropathy
10.3760/cma.j.issn.1001-7097.2014.12.007
- VernacularTitle:醛固酮受体拮抗剂对肥胖相关肾小球病的影响
- Author:
Jing DONG
;
Hong CHENG
;
Min YANG
;
Yanyan WANG
;
Hongrui DONG
;
Hongliang RUI
;
Yipu CHEN
- Publication Type:Journal Article
- Keywords:
Aldosterone;
Spirolactone;
Podocytes;
Obesity-related glomerulopathy
- From:
Chinese Journal of Nephrology
2014;(12):919-924
- CountryChina
- Language:Chinese
-
Abstract:
Objective To examine whether aldosterone contribute to obesity related glomerular disease. Methods C57BL/6J mice were randomly divided into three groups: a control group (low?fat?diet, n=10), a model group (high?fat?diet, n=10) and a intervention group (high?fat?diet, n=12). After 8 weeks intervention group were treated with a mineralocorticoid receptor antagonist, spirolactone (SPL).The physicochemical indexes and the renal pathology of the three groups were all detected. The mRNA and protein expressions of podocyte marker protein were determined by real?time PCR and Western blotting, respectively. Results Compared with the control group, body weight, kidney weight, Lee ’s index, fat index, blood cholesterol, blood triglyceride, creatinine clearance rate, urinary protein excretion, glomerular average diameter, glomerular foot process average width were significantly up ? regulated (P<0.05); The mRNA and protein expression of nephrin, podocin, podoplanin and podocalyxin were significantly down?regulated in model group (P<0.05). Meanwhile, these changes were attenuated by SPL. Conclusion Aldosterone can participate in the process of obesity? related renal injury, and these can be attenuated by mineralocorticoid receptor antagonist, spirolactone. This gives us preliminary clues to treat ORG.
